Press release
Read more
Pharming Group Interim Report on Financial Results for the First Quarter 2018
Pharming presents its (unaudited) financial report for the quarter ended 31 March 2018.
News
Press release
Read more
A global awareness day for a rare life-threatening condition: World HAEday, 16th May 2018
On May 16th Hereditary Angioedema (HAE) patient organizations from around the world, led by HAEi (The international HAE patient organisation), come together to support the global awareness day for Hereditary Angioedema; a rare life-threatening condition.
Press release
Read more
Pharming announces publication of 2017 Annual Report and invitation to Annual General Meeting of Shareholders
The Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, announces publication of its 2017 annual report and issues an invitation to its Annual General Meeting for all shareholders.
Press release
Read more
Pharming enters the Euronext Amsterdam SmallCap-index (AScX)
Today Pharming announced that it has been included in the Euronext Amsterdam SmallCap-index (AScX). On entry into the AScX, Pharming has become one of the larger index members.
Press release
Read more
Pharming announces issue of shares as majority of remaining warrants are exercised
Today Pharming announced that during the period of 7 to 9 March, it has issued a total of 6,315,235 new shares following the exercise of warrants representing a total of 9,174,372 shares.
Press release
Read more
Pharming Group Report on Preliminary Financial Results for 2017
Pharming presents its preliminary (unaudited) financial report for the full year ended 31 December 2017.
Press release
Read more
Pharming announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST® for Prophylaxis of Hereditary Angioedema Attacks
Today Pharming announced that the U.S. Food and Drug Administration (FDA) has accepted for review Pharming’s supplemental Biologics License Application (sBLA) for RUCONEST® [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema (HAE).
Press release
Read more
Pharming announces further conversion of its Ordinary Convertible Bonds
Today Pharming announced that it has issued a total of 25,441,901 new shares and €1.9 million of cash to redeem €7.7 million of the Ordinary Convertible Bonds (“Bonds”).
Press release
Read more
Pharming announces significant conversion of its Ordinary Convertible Bonds
Today Pharming announced that it has issued a total of 10,563,380 new shares from within the amount allocated to conversion of the Ordinary Convertible Bonds (the “Bonds”) to redeem €3.0 million of the Bonds being converted by their holders, thereby reducing the outstanding amount of the Bonds to €8.5 million.
Press release
Read more
Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST® for Prophylaxis of Hereditary Angioedema Attacks
Today Pharming announced that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (“FDA”) for RUCONEST® [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema (“HAE”).